Literature DB >> 32818235

Predicting Disease Severity and Outcome in COVID-19 Patients: A Review of Multiple Biomarkers.

Youley Tjendra1, Abdulaziz F Al Mana1, Andrea P Espejo2, Yamac Akgun1, Nicolas C Millan1, Carmen Gomez-Fernandez1, Carolyn Cray3.   

Abstract

CONTEXT.—: An abundance of clinical reports focused on specific laboratory parameters have been reported on coronavirus disease 19 (COVID-19), but a systematic analysis synthesizing these findings has not been performed. OBJECTIVE.—: To review and summarize the current available literature on the predictive role of various biomarkers in COVID-19 patients. DATA SOURCES.—: A literature search was performed using databases including PubMed, medRxiv, and bioRxiv. A total of 72 papers were reviewed, including 54 peer-reviewed papers and 18 non-peer-reviewed preprints. CONCLUSIONS.—: Although the markers are considered nonspecific, acute-phase reactants, including C-reactive protein (CRP), ferritin, serum amyloid A (SAA), and procalcitonin, were reported as sensitive markers of acute COVID-19 disease. Significantly elevated white blood cell count; marked lymphopenia; decreased CD3, CD4, or CD8 T-lymphocyte counts; high neutrophil count; thrombocytopenia; and markedly elevated inflammatory biomarkers were associated with severe disease and the risk of developing sepsis with rapid progression. Trends observed by serial laboratory measurements during hospitalization, including progressive decrease of lymphocyte count, thrombocytopenia, elevated CRP, procalcitonin, increased liver enzymes, decreased renal function, and coagulation derangements, were more common in critically ill patient groups and associated with a high incidence of clinical complications. Elevated interleukin 6 level and markedly increased SAA were most often reported in severely and critically ill patients. Indicators of systemic inflammation, such as neutrophil to lymphocyte ratio, systemic immune-inflammation index, or COVID-19 Severity Score, may be used to predict disease severity, outcome, and mortality. Interpretation of the data reported in the studies reviewed here is limited because of the study design (mostly retrospective), limited sample size, and a lack of defined clinical criteria.
© 2020 College of American Pathologists.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32818235     DOI: 10.5858/arpa.2020-0471-SA

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  48 in total

1.  Relationship Between Platelet Count and In-hospital Mortality in Adult Patients With COVID-19: A Retrospective Cohort Study.

Authors:  Qilin Yang; Jun Gao; Xiaomei Zeng; Junyu Chen; Deliang Wen
Journal:  Front Med (Lausanne)       Date:  2022-06-14

2.  A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Moderna COVID-19 Vaccine (mRNA-1273).

Authors:  Brett Leav; Walter Straus; Phil White; Alison Leav; Tashawnee Gaines; Grace Maggiacomo; Denny Kim; Emily R Smith; Marc Gurwith; Robert T Chen
Journal:  Vaccine       Date:  2022-06-09       Impact factor: 4.169

Review 3.  The Role of Biomarkers in Hospitalized COVID-19 Patients With Systemic Manifestations.

Authors:  Michael Schneider
Journal:  Biomark Insights       Date:  2022-06-26

Review 4.  Potential role of biochemical markers in the prognosis of COVID-19 patients.

Authors:  Apeksha Niraula; Nirmal Baral; Madhab Lamsal; Mahima Bataju; Saroj Thapa
Journal:  SAGE Open Med       Date:  2022-07-05

Review 5.  Immune profiling of COVID-19: preliminary findings and implications for the pandemic.

Authors:  Holden T Maecker
Journal:  J Immunother Cancer       Date:  2021-05       Impact factor: 13.751

6.  The Systemic Inflammation Index on Admission Predicts In-Hospital Mortality in COVID-19 Patients.

Authors:  Alessandro G Fois; Panagiotis Paliogiannis; Valentina Scano; Stefania Cau; Sergio Babudieri; Roberto Perra; Giulia Ruzzittu; Elisabetta Zinellu; Pietro Pirina; Ciriaco Carru; Luigi B Arru; Alessandro Fancellu; Michele Mondoni; Arduino A Mangoni; Angelo Zinellu
Journal:  Molecules       Date:  2020-12-04       Impact factor: 4.411

7.  Characteristics of COVID-19 Patients Based on the Results of Nucleic Acid and Specific Antibodies and the Clinical Relevance of Antibody Levels.

Authors:  Hao Chen; Rundong Qin; Zhifeng Huang; Li He; Wenting Luo; Peiyan Zheng; Huimin Huang; Hui Wang; Baoqing Sun
Journal:  Front Mol Biosci       Date:  2021-01-12

8.  Association of hyperglycaemia with hospital mortality in nondiabetic COVID-19 patients: A cohort study.

Authors:  M Mamtani; A M Athavale; M Abraham; J Vernik; A R Amarah; J P Ruiz; A J Joshi; M Itteera; S D Zhukovski; R P Madaiah; B C White; P Hart; H Kulkarni
Journal:  Diabetes Metab       Date:  2021-03-26       Impact factor: 6.041

9.  Remdesivir, Renal Function and Short-Term Clinical Outcomes in Elderly COVID-19 Pneumonia Patients: A Single-Centre Study.

Authors:  Edoardo Biancalana; Martina Chiriacò; Paolo Sciarrone; Alessandro Mengozzi; Sandra Mechelli; Stefano Taddei; Anna Solini
Journal:  Clin Interv Aging       Date:  2021-06-03       Impact factor: 4.458

10.  The Clinical Significance of Procalcitonin Elevation in Patients over 75 Years Old Admitted for COVID-19 Pneumonia.

Authors:  Andrea Ticinesi; Antonio Nouvenne; Beatrice Prati; Loredana Guida; Alberto Parise; Nicoletta Cerundolo; Chiara Bonaguri; Rosalia Aloe; Angela Guerra; Tiziana Meschi
Journal:  Mediators Inflamm       Date:  2021-06-28       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.